- Home
- SYTA vs NCNA Comparison
SYTA vs NCNA Comparison
Compare SYTA & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYTA
- NCNA
- Stock Information
- Founded
- SYTA 1986
- NCNA 1997
- Country
- SYTA Canada
- NCNA United Kingdom
- Employees
- SYTA N/A
- NCNA N/A
- Industry
- SYTA Telecommunications Equipment
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- SYTA Telecommunications
- NCNA Health Care
- Exchange
- SYTA Nasdaq
- NCNA Nasdaq
- Market Cap
- SYTA 3.1M
- NCNA 3.4M
- IPO Year
- SYTA 2020
- NCNA 2017
- Fundamental
- Price
- SYTA $2.11
- NCNA $0.89
- Analyst Decision
- SYTA
- NCNA Buy
- Analyst Count
- SYTA 0
- NCNA 2
- Target Price
- SYTA N/A
- NCNA $25.00
- AVG Volume (30 Days)
- SYTA 701.7K
- NCNA 117.7K
- Earning Date
- SYTA 05-15-2025
- NCNA 05-15-2025
- Dividend Yield
- SYTA N/A
- NCNA N/A
- EPS Growth
- SYTA N/A
- NCNA N/A
- EPS
- SYTA N/A
- NCNA N/A
- Revenue
- SYTA $11,988,979.00
- NCNA N/A
- Revenue This Year
- SYTA $75.92
- NCNA N/A
- Revenue Next Year
- SYTA $19.72
- NCNA N/A
- P/E Ratio
- SYTA N/A
- NCNA N/A
- Revenue Growth
- SYTA 41.59
- NCNA N/A
- 52 Week Low
- SYTA $1.82
- NCNA $0.69
- 52 Week High
- SYTA $885.60
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- SYTA 37.74
- NCNA 48.84
- Support Level
- SYTA $1.88
- NCNA $0.81
- Resistance Level
- SYTA $2.24
- NCNA $1.34
- Average True Range (ATR)
- SYTA 0.33
- NCNA 0.14
- MACD
- SYTA 0.10
- NCNA 0.02
- Stochastic Oscillator
- SYTA 12.43
- NCNA 30.66
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The Company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.